Frontier IP Group plc ex scientia Limited - Partnership with Evotec AG
April 27 2016 - 1:01AM
RNS Non-Regulatory
TIDMFIPP
Frontier IP Group plc
27 April 2016
RNS REACH
AIM: FIPP
27 April 2016
Frontier IP Group Plc
("Frontier IP" or the "Group")
ex scientia Limited - Partnership with Evotec AG
Frontier IP, which specialises in the commercialisation of
intellectual property, is pleased to announce that its portfolio
company ex scientia Limited ("ex scientia") and Evotec AG have
entered into a partnership to discover bispecific small molecule
immuno-oncology therapeutics.
The full text of this announcement is set out below.
Hamburg, Germany, Dundee, UK - 26 April 2016: Evotec AG
(Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and ex
scientia Ltd (Dundee, UK) today announced a collaboration with the
objective to discover and develop first-in-class bispecific small
molecule immuno-oncology therapies. Ex scientia will contribute its
unique algorithmic design platform while Evotec, mainly through its
Toulouse site, will be responsible for medicinal chemistry, in
vitro and in vivo pharmacology as well as development capabilities
and expertise.
Application of bispecific small molecules is an exciting
strategy to significantly expand and enhance efficacy beyond
conventional single target therapies. The initial focus will be
cancer-related adenosine targets which are increasingly recognised
to play important roles in immuno-oncology. Combining
adenosine-based mechanisms with related targets holds great promise
in boosting efficacy and addressing larger patient populations
through a single small molecule drug.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented:
"Polypharmacy is a widely used strategy to manage diseases more
effectively. Ex scientia has built an outstanding platform to
purposely design bispecific small molecules that can address
multiple targets through a single molecule. Together we are well
positioned to discover and develop a new generation of small
molecule immuno-oncology therapies."
Commenting on the relationship, Andrew Hopkins, CEO, ex
Scientia, said: "This is an ideal partnership to develop an
innovative immuno-oncology portfolio where our focus is on
delivering efficacious drug candidates to tackle the inherent
challenges of the complex biology. Evotec have an excellent track
record in project delivery and their proven track record in
regarding efficiency gains in drug discovery chime with our
own."
This is a co-owned, risk-shared-partnership, no further
financial details were disclosed.
ENDS
Enquiries
Frontier IP Group Plc T: 0131 240 1251
Neil Crabb, Chief Executive
Cantor Fitzgerald Europe T: 020 7894 7000
(Nominated Adviser and Joint
Broker)
David Foreman, Catherine
Leftley, Corporate Finance
David Banks, Sales
Peterhouse Corporate Finance T: 020 7469 0935
Limited
(Joint Broker)
Lucy Williams
Kreab T: 020 7074 1800
(Financial PR)
Robert Speed, Matthew Jervois
Notes to Editor:
About Frontier IP Group plc
www.frontierip.co.uk.
Frontier IP specialises in assisting institutions and companies
in the commercialisation and exploitation of their intellectual
property. It establishes formal and informal relationships with
sources of exploitable IP, principally universities. Its core
business is building and growing a portfolio of equity stakes in
spin-out companies by taking an active involvement in the
commercialisation and funding of these businesses.
About ex Scientia Limited
www.exscientia.co.uk
ex scientia is a privately owned company developing new
medicines for a wide range of human diseases where improved
efficacy is required. ex scientia is the first company to develop a
systematic algorithmic discovery platform to automatically design
molecules to complex target product profiles. ex scientia has
successfully applied its algorithm-driven design principles to
developed novel molecules with complex bispecifics, and phenotypic
product profiles. Adopting this strategy increases the efficiency
and effectiveness of drug discovery. As the industry pioneer of
automated drug design, ex scientia aims to create exceptional value
for its partners, by delivering effective treatments to the
clinic.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEQLFLQZFBBBD
(END) Dow Jones Newswires
April 27, 2016 02:01 ET (06:01 GMT)
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From Apr 2024 to May 2024
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From May 2023 to May 2024